Mileutis Appoints Industry Experts to Drive Residue-Free Mastitis Treatment Innovation and Commercialization

Mileutis, an Israeli biopharmaceutical firm transforming the way farmers and veterinarians address various diseases, today announced the appointment of three renowned experts to its Scientific Advisory Board of Directors, chaired by Jose Iscovich. Dr. William Baker, Vaughn Kubiak, and Dr. Jean-Paul Prieels join Mileutis as the company gears up for large-scale commercialization of its flagship products, Imilac™ - a residue-free intramammary solution for managing, treating, and preventing bovine mastitis at dry-off. They will collaborate with existing Scientific Advisory Board members Thomas D. Overbay and Kobi Lustgarten. With 30 years of experience in veterinary medicine R&D, Dr. William Baker has worked as a veterinary drug development consultant for Pfizer Animal Health/Zoetis Research and Development. He led Regulatory Affairs for several animal health development programs at Pfizer that achieved FDA approvals, including Dectomax antiparasitic and Draxxin antibiotics for cattle. Baker also served on Zoetis' veterinary medicine leadership team. Vaughn Kubiak brings over 40 years of global animal health experience, primarily in the development, licensure, and maintenance of veterinary biologics. Throughout his career, Kubiak has contributed to the development and enhancement of conventional and innovative immunological veterinary medicinal products for major species. He held management positions at Zoetis for 17 years in Regulatory Affairs, Biologics Process Development, and Biological Analytical Development. Dr. Jean-Paul Prieels retired as Senior Vice President of Vaccines R&D at GlaxoSmithKline Biologicals in 2011, after serving as a senior executive for over 23 years. At GlaxoSmithKline, he led the extramural R&D team and was responsible for vaccine R&D preclinical activities in Rixensart, Belgium. Dr. Prieels played a vital role in developing several commercially available vaccines, such as Rotarix, Cervarix, Synflorix, and Shingrix. "Mileutis is a knowledge-driven company committed to adopting groundbreaking solutions to enhance animal healthcare for the benefit of humanity," says David Javier Iscovich, CEO and Co-Founder of Mileutis. "Our scientific and management teams possess extensive expertise in biopharmaceutical R&D, animal health, drug development, and clinical trials. The addition of these three industry leaders, who are renowned in their respective fields, to the Mileutis Scientific Advisory Board of Directors, reinforces the organization's innovative work." Founded in 2004 and led by David Javier Iscovich, Mileutis' R&D effort is spearheaded by Dr. Jose Iscovich, the company's president and co-founder. In October 2020, the firm secured $20 million in funding from NovaQuest Capital Management, marking the North Carolina-based private equity firm's inaugural investment in animal health. Mastitis, the most common and expensive disease to treat in dairy herds globally, is targeted by Mileutis' first-of-its-kind, residue-free peptide Imilac™. This novel solution is part of a series of patented products addressing the mounting concern of antibiotic resistance and overuse in the global dairy sector. Mileutis' leading products are projected to generate potential annual revenue exceeding $1 billion worldwide.